Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00408603 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
A Phase 2 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT00408603 is a Phase 2 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 183 participants.
The verdict
NCT00408603, a Phase 2 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
Interventions
- DRUG Voreloxin Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2006-12-20 |
| Est. Completion | 2010-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00408603
The ClinicalTrials.gov registry entry for NCT00408603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Voreloxin Injection is the first listed.
NCT00408603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00408603 about?
NCT00408603 is a clinical study titled "Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer". The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
What is the current status of trial NCT00408603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2006-12-20. Estimated completion is 2010-06-09.
What interventions are being tested in trial NCT00408603?
The interventions under investigation include: Voreloxin Injection (DRUG).
Who is sponsoring clinical trial NCT00408603?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.